Voltage-gated sodium channel, tetrodotoxin-resistant (TTX-r Nav)

Voltage-gated sodium channels (Nav) that are resistant to tetrodotoxin (TTX) represent a distinct subset of the sodium channel family, primarily comprising the Nav1.5, Nav1.8, and Nav1.9 isoforms (Goldin, 2001; PubMed: 11574755). Unlike TTX-sensitive channels, which are inhibited by nanomolar concentrations of the toxin, these channels require micromolar concentrations for blockade due to specific amino acid substitutions in the pore region. Nav1.5 is the primary sodium channel in the heart, essential for the initiation and propagation of the cardiac action potential, and is a target for class I antiarrhythmic drugs (Abriel, 2007; PubMed: 17916530). In contrast, Nav1.8 and Nav1.9 are highly expressed in the dorsal root ganglia (DRG) and are critical mediators of nociceptive signaling and the development of chronic pain states (Bennett et al., 2019; PubMed: 30733148). Therapeutic targeting of TTX-resistant channels is a major focus in drug development, particularly for pain management and cardiology. Selective inhibitors of Nav1.8, such as suzetrigine (VX-548), are being developed to provide potent analgesia without the central nervous system side effects or addiction potential associated with opioids (Vertex Pharmaceuticals, 2024). Conversely, mutations in the genes encoding these channels (SCN5A, SCN10A, SCN11A) are linked to various channelopathies, including Brugada syndrome, long QT syndrome, and small fiber neuropathy. Understanding the specific pharmacology of these channels is vital for developing treatments that can modulate excitability in a tissue-specific manner while avoiding off-target cardiac or neurological toxicity.

Other names

TTX-resistant sodium channelsTTX-r NavTTX-r VGSCsSCN5A/SCN10A/SCN11A groupTetrodotoxin-insensitive sodium channels

Inhibition of sodium ion influx through the alpha-subunit pore, often by stabilizing the inactivated state of the channel to suppress neuronal or cardiac hyperexcitability.